Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PERCOCET vs DAWNZERA (AUTOINJECTOR)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception and emotional response. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis and exerting analgesic and antipyretic effects.
DAWNZERA (autoinjector) contains epinephrine, a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction via alpha-1 receptors, bronchodilation via beta-2 receptors, and increased heart rate and contractility via beta-1 receptors, reversing anaphylactic symptoms.
Management of moderate to moderately severe pain (FDA-approved),Off-label: severe pain when other analgesics are inadequate (individualized use)
Emergency treatment of allergic reactions (Type I), including anaphylaxis, to insect stings, foods, drugs, and other allergens, as well as idiopathic and exercise-induced anaphylaxis.
One tablet (5 mg oxycodone/325 mg acetaminophen) every 6 hours as needed for pain; maximum 12 tablets per day.
60 mg subcutaneously once daily, administered at approximately the same time each day.
Oxycodone: 3.5–4.5 hours (terminal) in normal renal function; prolonged in hepatic/renal impairment (up to 6–12 hours). Acetaminophen: 2–3 hours (terminal) in overdose, extended with hepatic injury.
Terminal elimination half-life is 12-15 hours in healthy adults, allowing once-daily dosing; prolonged in renal impairment.
Oxycodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (noroxycodone, oxymorphone). Acetaminophen: hepatic via glucuronidation (UGT1A1/1A6), sulfation, and minor CYP2E1 oxidation.
Epinephrine is metabolized primarily by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) to metanephrine, normetanephrine, vanillylmandelic acid (VMA), and other metabolites.
Oxycodone: primarily renal (up to 19% as unchanged drug, 50% as noroxycodone and oxymorphone metabolites); about 10% biliary/fecal. Acetaminophen: renal (majority as glucuronide and sulfate conjugates, about 5% unchanged).
Primarily renal excretion of unchanged drug (approximately 60-70%) with minor biliary/fecal elimination (20-30%).
Oxycodone: 38–45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10–25% bound to albumin (minimal).
92-95% bound primarily to albumin.
Oxycodone: Vd approximately 2.6 L/kg (extensive tissue distribution). Acetaminophen: Vd approximately 0.9 L/kg (total body water).
Vd is approximately 0.2-0.3 L/kg, indicating distribution mainly in extracellular fluid.
Oxycodone: oral bioavailability 60–87% (immediate-release). Acetaminophen: oral bioavailability 85–98% (first-pass metabolism minimal).
Subcutaneous: 75-80%; intramuscular: 80-85%.
GFR >60 m L/min: no adjustment; GFR 30-60 m L/min: dose every 8 hours; GFR <30 m L/min: avoid use or use with extreme caution, consider reducing dose to 50% or extending interval to every 12 hours; not recommended in ESRD.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min). For severe renal impairment (e GFR <30 m L/min) or end-stage renal disease, use is not recommended due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce total daily dose by 50%; Child-Pugh C: avoid use.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended for moderate to severe hepatic impairment (Child-Pugh B or C) due to lack of data.
Not FDA-approved for children <18 years; off-label: 0.1-0.2 mg/kg oxycodone (max 5 mg) plus 5-10 mg/kg acetaminophen every 4-6 hours; total acetaminophen not to exceed 75 mg/kg/day or 4 g/day.
Not approved for use in pediatric patients; safety and efficacy have not been established.
Start with low end of dosing, e.g., 2.5 mg oxycodone/325 mg acetaminophen every 6 hours; monitor renal function and avoid >4 g/day acetaminophen; titrate cautiously due to increased sensitivity and fall risk.
No specific dose adjustment required; elderly patients may have increased sensitivity, but standard adult dosing is recommended. Monitor for adverse effects.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of any dosage (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; CYP3A4 inhibitors or discontinuation of CYP3A4 inducers may cause fatal respiratory depression; concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
None.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; seizures; serotonin syndrome; adrenal insufficiency; hepatotoxicity (acetaminophen); increased risk of pancreatitis (if combined with alcohol); risk of overuse for acetaminophen.
Administration should be into the anterolateral aspect of the thigh, not into the gluteal muscle or veins. Patients with preexisting cardiovascular disease, hypertension, diabetes, hyperthyroidism, or elderly may be at increased risk of adverse effects. Use with caution in patients receiving beta-blockers or MAO inhibitors.
Hypersensitivity to oxycodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; severe hepatic impairment (acetaminophen hepatotoxicity risk).
No absolute contraindications to epinephrine in life-threatening anaphylaxis. Relative contraindications include hypersensitivity to epinephrine or any component of the autoinjector.
Avoid alcohol and grapefruit juice. Alcohol can potentiate hepatotoxicity from acetaminophen and CNS depression from oxycodone. Grapefruit juice may increase oxycodone levels, enhancing sedative and respiratory depressant effects. No other significant food interactions.
No direct food interactions. However, after recovery from severe hypoglycemia, provide oral carbohydrates (e.g., juice, glucose tablets) to prevent recurrence and replenish glycogen stores.
Percocet (oxycodone/acetaminophen) is pregnancy category C prior to 30 weeks gestation and category D after 30 weeks. First trimester: No clear evidence of major malformations, but opioid use may be associated with neural tube defects and gastroschisis. Second trimester: Risk of miscarriage, intrauterine growth restriction. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery. Acetaminophen is considered safe in therapeutic doses but overdose is hepatotoxic to fetus.
Pregnancy Category B. No evidence of fetal harm in animal studies; however, no adequate human studies. Risk cannot be excluded but is considered low. First trimester: Theoretical risk based on mechanism (CGRP antagonism); no human data. Second and third trimesters: No reported adverse fetal outcomes.
Oxycodone is excreted into breast milk; relative infant dose is approximately 1-2% of maternal weight-adjusted dose. M/P ratio (milk/plasma) is about 3.2:1 for oxycodone. Acetaminophen M/P ratio ~1.0. Low levels expected, but monitor infant for sedation and poor feeding. Caution with maternal high doses or prolonged use; avoid if mother is ultra-rapid CYP2D6 metabolizer due to risk of toxicity.
Not recommended due to unknown excretion in human milk. M/P ratio not established. Consider risk of infant exposure given monoclonal antibody structure; likely present in milk but limited absorption from infant GI tract.
During pregnancy, increased plasma volume and hepatic metabolism may require higher doses of oxycodone to achieve analgesic effect. However, due to fetal risks, use lowest effective dose for shortest duration. No specific dose adjustments are validated; clinical response should guide dosing. Acetaminophen dosing remains unchanged but avoid exceeding 3 g/day in pregnancy.
No dose adjustment recommended based on pharmacokinetic changes in pregnancy. However, limited data; use only if clearly needed.
Percocet contains oxycodone and acetaminophen; the acetaminophen component limits total daily dosing to avoid hepatotoxicity (max 4 g/day in adults, lower in liver disease or alcohol use). Due to oxycodone, it is a Schedule II controlled substance with high abuse potential. Constipation is a common adverse effect; consider prophylactic bowel regimen (e.g., docusate, senna). Respiratory depression risk is dose-related and increased with concurrent CNS depressants. Use with caution in elderly, renal impairment, or sleep apnea. Tolerance and dependence develop with prolonged use. Taper to discontinue after chronic use. Avoid in patients with known hypersensitivity to opioids or acetaminophen.
DAWNZERA (glucagon) autoinjector is used for severe hypoglycemia. Administer intramuscularly or subcutaneously into the outer thigh; avoid intravenous injection due to risk of thromboembolism. Onset of action is 5-20 minutes. Monitor for nausea and vomiting, which are common. Due to short half-life (8-18 minutes), follow with oral carbohydrates once patient regains consciousness. Caution in patients with pheochromocytoma or insulinoma as glucagon may stimulate catecholamine release or cause rebound hyperglycemia.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other sedatives (e.g., benzodiazepines, muscle relaxants) as they increase risk of severe drowsiness and respiratory depression.,Do not drive or operate heavy machinery until you know how this medication affects you; it may cause dizziness or drowsiness.,Do not exceed 4,000 mg of acetaminophen per day from all sources; check over-the-counter medications for acetaminophen content.,Stop taking and seek immediate medical attention if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, abdominal pain.,Common side effects include constipation, nausea, vomiting, and drowsiness. Increase fluid and fiber intake to prevent constipation.,This drug has a high risk of addiction and dependence. Store securely out of reach of others. Do not share with others.,Do not suddenly stop taking after prolonged use; a gradual taper is needed to avoid withdrawal symptoms.,Contact your doctor if pain is not controlled or if you experience signs of allergic reaction (rash, swelling, trouble breathing).
Always keep DAWNZERA accessible and ensure family/caregivers know how to use it.,Inject into the outer thigh through clothing if necessary; avoid injecting into a vein.,After injection, turn patient on their side to prevent aspiration if vomiting occurs.,Seek emergency medical help immediately after use, even if symptoms improve.,Do not reuse the autoinjector; dispose of it properly after single use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PERCOCET vs DAWNZERA (AUTOINJECTOR), answered by our medical review team.
PERCOCET is a Opioid Analgesic Combination that works by Oxycodone is a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception and emotional response. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis and exerting analgesic and antipyretic effects.. DAWNZERA (AUTOINJECTOR) is a Unknown that works by DAWNZERA (autoinjector) contains epinephrine, a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction via alpha-1 receptors, bronchodilation via beta-2 receptors, and increased heart rate and contractility via beta-1 receptors, reversing anaphylactic symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PERCOCET and DAWNZERA (AUTOINJECTOR) depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PERCOCET is: One tablet (5 mg oxycodone/325 mg acetaminophen) every 6 hours as needed for pain; maximum 12 tablets per day.. The standard adult dose of DAWNZERA (AUTOINJECTOR) is: 60 mg subcutaneously once daily, administered at approximately the same time each day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PERCOCET and DAWNZERA (AUTOINJECTOR) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PERCOCET is classified as Category C. Percocet (oxycodone/acetaminophen) is pregnancy category C prior to 30 weeks gestation and category D after 30 weeks. First trimester: No clear evidence of major malformations, but. DAWNZERA (AUTOINJECTOR) is classified as Category C. Pregnancy Category B. No evidence of fetal harm in animal studies; however, no adequate human studies. Risk cannot be excluded but is considered low. First trimester: Theoretical r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.